China's Latest Cloned-Monkey Experiment Is an Ethical Mess
By Ryan F. Mandelbaum,
Gizmodo
| 01. 23. 2019
Chinese researchers have cloned five gene-edited monkeys with a host of genetic disease symptoms, according to two scientific papers published today.
The researchers say they want to use the gene-edited macaques for biomedical research; basically, they hope that engineering sick primates will reduce the total number of macaques used in research around the world. But their experiment is a minefield of ethical quandaries—and makes you wonder whether the potential benefits to science are enough to warrant all of the harm to these monkeys.
The researchers began by using CRISPR/Cas9 to alter the DNA of a donor macaque. CRISPR/Cas9 is the often-discussed gene editing tool derived from bacteria that combines repeating sequences of DNA and a DNA-cutting enzyme in order to customize DNA sequences. Experts and the press have heralded it as an important advance due to how quickly and cheaply it can alter DNA, but recent research has demonstrated it may cause more unintended effects than previously thought.
In this experiment, the researchers turned off a gene called BMAL-1, which is partially responsible for the circadian rhythm. Monkeys with this...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...